乳腺癌骨转移疗效评估:18F-氟化物代谢通量测量是否优于18F-氟化物PET/CT SUV测量
本研究纳入12例开始内分泌治疗的乳腺癌骨转移患者,于治疗前及治疗8周后行静态18F-氟化物PET/CT,计算骨转移灶Ki、SUVmax和SUVmean的百分比变化,以24周内临床缓解为参考标准。结果显示,4例临床进展患者中Ki均显著升高,而SUVmax仅3例、SUVmean仅2例升高;进展患者Ki平均升高89.7%,高于SUVmax的41.8%和SUVmean的43.5%(P < 0.001)。结论认为Ki较SUVmax和SUVmean更可靠地区分进展与非进展。
要点
- 12例乳腺癌骨转移患者内分泌治疗8周后,Ki在4例临床进展者中均升高>25%。
- 8例非进展患者中,Ki下降或稳定7例,SUVmax 5例,SUVmean 6例。
- 进展患者Ki平均升高89.7%,SUVmax 41.8%,SUVmean 43.5%(P < 0.001)。
核心结论
- 内分泌治疗8周后,Ki较SUVmax和SUVmean更可靠地区分乳腺癌骨转移的临床进展与非进展。
研究设计与样本
- 纳入12例因新发或进展性骨转移开始内分泌治疗的乳腺癌患者,于治疗前和治疗8周后行注射后60分钟静态18F-氟化物PET/CT。
- 于注射后55和85分钟采集静脉血测定血浆18F-氟化物活度浓度,采用既往验证方法计算骨转移灶Ki。
- 从每例患者同一索引病灶(≤5个)计算Ki、SUVmax和SUVmean的百分比变化,以24周内2名不知PET结果的肿瘤科医师共识判定的临床缓解为参考标准。
主要发现
- 4例临床进展患者中,Ki均显著升高(>25%),SUVmax 3例升高,SUVmean 2例升高。
- 8例非进展患者中,Ki下降或稳定7例,SUVmax 5例,SUVmean 6例。
- 4例进展患者Ki较基线的平均百分比升高为89.7%,SUVmax为41.8%,SUVmean为43.5%(P < 0.001)。
关键数值与推荐
- 临床进展定义为24周内临床评估为进展性疾病(PD),由2名不知PET结果的肿瘤科医师共识判定。
- Ki显著升高判定为较基线升高>25%。
- 进展患者Ki平均升高89.7% vs SUVmax 41.8%和SUVmean 43.5%(P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our purpose was to establish whether noninvasive measurement of changes in 18F-fluoride metabolic flux to bone mineral (Ki) by PET/CT can provide incremental value in response assessment of bone metastases in breast cancer compared with SUVmax and SUVmeanMethods: Twelve breast cancer patients starting endocrine treatment for de novo or progressive bone metastases were included. Static 18F-fluoride PET/CT scans were acquired 60 min after injection, before and 8 wk after commencing treatment. Venous blood samples were taken at 55 and 85 min after injection to measure plasma 18F-fluoride activity concentrations, and Ki in individual bone metastases was calculated using a previously validated method. Percentage changes in Ki, SUVmax, and SUVmean were calculated from the same index lesions (≤5 lesions) from each patient. Clinical response up to 24 wk, assessed in consensus by 2 experienced oncologists masked to PET imaging findings, was used as a reference standard. Results: Of the 4 patients with clinically progressive disease (PD), mean Ki significantly increased (>25%) in all, SUVmax in 3, and SUVmean in 2. Of the 8 non-PD patients, Ki decreased or remained stable in 7, SUVmax in 5, and SUVmean in 6. A significant mean percentage increase from baseline for Ki, compared with SUVmax and SUVmean, occurred in the 4 patients with PD (89.7% vs. 41.8% and 43.5%, respectively; P < 0.001). Conclusion: After 8 wk of endocrine treatment for bone-predominant metastatic breast cancer, Ki more reliably differentiated PD from non-PD than did SUVmax and SUVmean, probably because measurement of SUV underestimates fluoride clearance by not considering changes in input function.
引用
- Azad GK, Siddique M, Taylor B, et al. Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of 18F-Fluoride Metabolic Flux Than with Measurement of 18F-Fluoride PET/CT SUV? J Nucl Med. 2018. PMID: 30042160. doi:10.2967/jnumed.118.208710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。